Altered excitatory synaptic activity is likely a key factor in the neuronal hyperexcitability of developmental cerebral malformations. Using a combined morphologic and molecular approach, we investigated the NMDA receptor and related protein composition in human epileptic patients affected by periventricular nodular heterotopia, subcortical band heterotopia, or focal cortical dysplasia. Our results indicate that expression levels of specific NMDA receptor subunits are altered in both cerebral heterotopia and cortical dysplasia. A selective increase in the NR2B subunit was present in all cortical dysplasia, whereas the expression level of NR2A and NR2B subunits was significantly downregulated in all patients with heterotopia. NR2B upregulation in cortical dysplasia was greater in the total homogenate than the postsynaptic membrane fraction, suggesting that mechanisms other than increased ionic influx through the postsynaptic membrane may sustain hyperexcitability in dysplastic neurons. In cerebral heterotopia, the NR2A and NR2B downregulation was accompanied by less evident reduction of the SAP97 and PSD-95 proteins of the MAGUK family, thus suggesting that NMDA impairment was associated with altered molecular structure of the postsynaptic membrane. Our results demonstrate that diverse human developmental malformations are associated with different alterations of the NMDA receptor, which may contribute to the genesis of epileptic phenomena.
INTRODUCTION
Human developmental brain abnormalities, commonly referred to as malformations of cortical development (MCD), are the result of genetically and/or epigenetically induced impairments of the processes underlying brain ontogenesis (1) . Human MCDs are an important cause of developmental disabilities and focal epilepsy, as clearly revealed by the large-scale use of magnetic resonance imaging (MRI) since the mid-1980s. Their relevance in determining difficultto-control epilepsy is underscored by the high percentages of neuropathologically proven MCDs (up to 20% in adults and 50% in children) in patients undergoing surgery for the treatment of drug-resistant seizures (2, 3) . The diverse types of MCDs have been classified according to their proposed ontogenesis (1) . Among the more frequently occurring MCDs, periventricular nodular heterotopia (PNH) (4) and subcortical band heterotopia (SBH) (5) are the result of impairment of neuronal migration mechanisms (6Y9), whereas focal cortical dysplasia (FCD) (10) is the result of altered cortical organization processes (1) .
The pathogenic mechanisms underlying epileptogenesis in human MCDs are far from being fully clarified, but alteration of excitatory synaptic activity is likely to play a role. The glutamatergic synapse is a functional ensemble of proteins that have been demonstrated to be key elements in neurodegeneration (11) . Among them, the NMDA (Nmethyl-D-aspartate) subtypes of glutamate receptors are dynamically associated to several signal transduction pathways, which may be activated by the Ca 2+ influx occurring on receptor opening and may in turn modulate the excitable response of the postsynaptic neuron (12) . Alterations in the structural organization of NMDA receptors have been described in the pathogenesis of neurologic disorders, including epilepsy (13Y15). Recent studies indeed demonstrated that NR2A/B NMDA receptor subunits are increased in surgical specimens from patients affected by FCD and that epileptiform activities in cortical slices from patients with FCD are sensitive to NR2B-specific inhibitors (16Y19). On the other hand, we have demonstrated reduced expression of NR2A/B receptor subunits in subcortical heterotopic neurons from surgical specimens of patients with PNH (20) .
The goal of this study was to investigate the composition of the NMDA receptor and related proteins in human patients affected by drug-resistant epilepsy associated with PNH or SBH or FCD. We focused our attention on NR1, NR2A, and NR2B subunits as a result of their high expression levels in cortical areas (21) . We used a combined morphologic, confocal immunofluorescence and Western blot analysis of cortical samples from surgically treated epileptic patients affected by microscopically verified brain malformations. Samples from 3 focal cryptogenic epilepsy and 2 nonepileptic patients were also analyzed as controls of comparable age. Our results indicate not only that the NMDA receptor organization is altered in both human cerebral heterotopia and cortical dysplasia, but also that the molecular structure of the postsynaptic membrane is different in neurons from different types of human MCDs.
MATERIALS AND METHODS

Human Patients
Human cortical samples were obtained from a total of 14 patients. Nine MCDs (4 PNH, 1 SBH, and 4 FCD) and 3 cryptogenic patients, all affected by drug-resistant focal epilepsy, were surgically treated for the relief of seizures at the Epilepsy Surgery Center BC. Munari[ of the Niguarda General Hospital in Milano. Before the surgery, highresolution magnetic resonance imaging and electroclinical data, including stereoelectroencephalography (SEEG) recordings in 9 cases, were used to define the surgical strategy and the epileptogenic areas to be ablated. In addition, 2 nonepileptic patients affected by brain tumors were surgically treated at the Neurosurgery Division of the Neurological Institute. In all patients, the examined cerebral specimens were removed for strictly therapeutic reasons after a formal informed consent was obtained.
Preparation of Cerebral Specimens
Cerebral samples were obtained from the epileptogenic areas to be ablated in the epileptic patients and from the cortical areas close to the brain tumors in the 2 nonepileptic subjects. Brain samples were quickly removed and immediately divided into 2 parts. The first part was fixed by immersion in 4% paraformaldehyde for 24 hours, maintained in 0.1 M phosphate buffer and 0.01% NaN 3 at pH 7.2, and then cut with a vibratome into 50-Km-thick sections. One series of sections was counterstained with 0.1% thionine for cytoarchitectural analysis and the adjacent sections processed for immunocytochemistry or immunofluorescence with antibodies recognizing neuronal and glial markers and NMDA receptors and related proteins. Sections from MCD and control cases were processed with the same experimental protocol in the same vials to allow a reliable comparison of data obtained from the different cases. The remaining adjacent part of all cerebral samples was snap-frozen by immersion in liquid nitrogen or on dry ice and maintained at Y80-C. Triton insoluble fraction (TIF) was obtained as previously described (22, 23) . The protein composition of the TIF fraction was carefully tested for the absence of presynaptic markers (i.e. synaptophysin and synaptotagmin). Similar protein yield was obtained in TIF purified from all patients and control tissues, and the same amount of TIF protein was applied to SDS-PAGE for Western blot analysis.
Antibodies
The following antibodies were used in immunocytochemical and Western blot analyses: 1) rabbit polyclonal antibodies directed against the NR2A or NR2B subunits of the rat NMDA receptor (from Chemicon International, Inc., Temecula, CA; or Molecular Probes, Eugene, OR); 2) mouse monoclonal (Pharmingen, Franklin Lakes, NJ) or rabbit polyclonal (Chemicon) antibodies directed against the NMDA NR1 subunit; 3) rabbit polyclonal antibody against the GluR1 subunit of the rat AMPA receptor (Chemicon); 4) mouse monoclonal antibody directed against the > subunit of Ca 2+ / calmodulin-dependent kinase II (>CaMKII; Chemicon); 5) rabbit polyclonal antibody against the activated phospho-thr-286->CaMKII (p286; Promega, Madison, WI); 6) mouse monoclonal antibody against the postsynaptic density protein PSD-95 (Affinity BioReagents Inc., Golden, CO); 7) rabbit polyclonal antibody against the postsynaptic density protein SAP97 (Affinity BioReagents); 8) mouse monoclonal antibody against a vertebrate DNA binding protein (NeuN; Chemicon) as a marker of differentiated neurons; 9) mouse monoclonal antibody against the calcium-binding protein parvalbumin (Swant, Bellinzona, Switzerland), as a marker for GABAergic inhibitory interneurons; 10) mouse monoclonal antibody against nonphosphorylated neurofilaments (SMI 311; Sternberger Monoclonals Inc., Lutherville, MD) as a marker of pyramidal neurons; and 11) mouse monoclonal antibody against the glial fibrillary acid protein (GFAP; Chemicon) as a marker of astroglial cells.
Immunocytochemistry and Immunofluorescence
Sections were pretreated with 4% sucrose in phosphatebuffered saline (PBS) for 30 minutes, with 100% methanol for 30 minutes, with 3% H 2 O 2 in PBS for 20 minutes, and then incubated with 10% normal goat serum and Triton 0.2% for 60 minutes to increase the penetration of antibodies, neutralize the endogenous peroxidase activity, and mask nonspecific adsorption sites. Sections were then incubated overnight at 4-C in the primary antisera (anti-NeuN, diluted 1:3,000; anti-SMI 311, 1:500; anti parvalbumin, 1:10,000; anti-GFAP, 1:500; anti-NR1, 1:100; anti-NR2B, 1:100; anti>CaMKII, 1:200; anti-p286, 1:200). After rinsing in PBS, the sections were incubated with biotinylated anti-mouse or anti-rabbit IgG (diluted 1:200) for 1 hour and then rinsed in PBS. The sections were then incubated for 1 hour with Extravidin (1:4,000, Sigma, St. Louis, MO). All immunoreagents were diluted in 1% normal serum in PBS. Peroxidase staining was obtained by reacting the sections in a solution containing 3-3'-diaminobenzidine (0.075%) and H 2 O 2 (0.002%) in 50 mM-Tris-HCl buffer at pH 7.6. Sections were then mounted on glass slides, air-dried, dehydrated, and coverslipped with DPX (Merck, Whitehouse Station, NJ). Slides were then analyzed with a Nikon Microphot FXA microscope and photographed with a Nikon Coolpix 5000 digital camera (Tokyo, Japan).
Selected sections were processed for confocal immunofluorescence to better visualize the subcellular localization of the considered cytologic markers. After pretreatments, sections were incubated overnight at 4-C with the anti-NR2B or -NR1
Copyright @ 2006 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited. primary antibodies. Sections were then incubated for 2 hours with Alexa Fluor 488 GAR (Molecular Probes; diluted 1:2,000), repeatedly rinsed, mounted on slides in water, coverslipped with Fluorsave (Calbiochem, Darmstadt, Germany), and examined on a Radiance 2100 confocal microscope (Bio-Rad, Hercules, CA). For double-labeling experiments, sections reacted with the anti-NR2B or antiparvalbumin antibodies were incubated with 10% normal goat serum for 60 minutes and then overnight at 4-C with the anti-GFAP or anti-NeuN primary antibodies, respectively. The sections were then incubated for 2 hours with Alexa Fluor 546 GAM (Molecular Probes; diluted 1:2,000), repeatedly rinsed, and mounted as described previously.
Western Blot Analysis
We used Western blot analysis to better quantify the protein levels of the NMDA receptor complex both in the homogenate and TIF fraction (23) and to obtain a more comprehensive evaluation of the different components of the postsynaptic glutamatergic synapse. The following proteins were analyzed: the NR1, NR2A, and NR2B NMDA subunits, the AMPA GluR1 subunit, total and p286-active form of >CaMKII, and the PSD-95 and SAP97 MAGUK proteins, which are responsible for the correct delivery and clustering of NR2A and NR2B subunits to the synapse (24) .
Proteins obtained in human extracts were separated by SDS-PAGE (7% acrylamide) and electroblotted onto nitrocellulose papers for 2.5 hours at 180 mA. The latter were blocked with 10% albumin in Tris-buffered saline (TBS) and then incubated for 1 to 2 hours at room temperature with the primary antibodies NR1 (diluted 1:1,000), NR2A (diluted 1:1,000), NR2B (1:1,000), PSD95 (1:1,000), SAP97 (1:1,000), >CaMKII (1:3,000), p286>CaMKII (1:1,000), or GluR1 (1:1,500) in 3% albumin in TBS. After extensive rinsing in TBS/Tween 0.1%, the nitrocellulose papers were incubated with horseradish peroxidaseYconjugated secondary antibodies (goat anti-rabbit, for polyclonal antibodies, dilution 1:10,000 [Pierce, Rockford, IL]; goat anti-mouse, for monoclonal antibodies, dilution 1:20,000 [Pierce]) and then the antigenY antibody complex revealed by enhanced chemiluminescence (Amersham International, Little Chalfont, U.K.). Total >CaMKII was used as loading control in both homogenate and TIF fraction as previously reported (25Y27).
Data Analysis and Statistical Evaluation
Quantitation of Western blot analysis was performed by means of computer-assisted imaging (Quantity-OneR System; Bio-Rad) and statistical evaluations were performed according to one-way analysis of variance followed by Bonferroni as post hoc comparison test.
Molecular Analysis of the Doublecortin (DCX) Gene
Peripheral blood was taken from patient 5, after obtaining informed consent, and DNA extracted using standard procedures. The 7 coding exons (exons 1C, 2Y7) of the DCX gene were amplified by PCR as previously described (28) . The PCR products were purified using the QIAEX II Gel Extraction Kit (Qiagen, Hilden, Germany) and analyzed by direct sequencing of both strands using the BigDye chaintermination chemistry on an ABI 3100 automated capillary sequencer (Applied Biosystems, Foster City, CA). Sequences of exons and intron/exon boundaries were then compared with the consensus sequences available in the GenBank database.
RESULTS
Malformations of Cortical Development and Control Patients
The clinical and magnetic resonance imaging data of all patients are summarized in the Table. In the 9 patients affected Clinical findings of the 9 patients affected by MCDs, the 3 cryptogenic, and the 2 nonepileptic controls analyzed in the present paper. PNH, periventricular nodular heterotopia; SBH, subcortical band heterotopia; FCD, focal cortical dysplasia; T1, T2, T4, first, second, and fourth temporal circonvolutions; F1, F2, first and second frontal circonvolutions.
by MCDs (6 males and 3 females; aged 7Y42 years), the duration of epilepsy ranged from 4 to 28 years, and the frequency of seizures before surgery ranged from 5 to 120 per month. On the basis of magnetic resonance imaging findings, PNH was diagnosed in the first 4 patients. The PNH extended from the paratrigonal region of the right lateral ventricle to the ipsilateral temporal ( Fig. 1A; patients 1 and 3) or parietal (patient 4) neocortex or largely involved the subcortical frontal white matter and overlying right frontal cortex in patient 2. Patient 5 presented a bilateral band of heterotopic neurons in the white matter of the temporo-occipital region (Fig. 1B) . Her magnetic resonance imaging features were slightly different from what observed for patients with Bclassic[ BH, because the heterotopic band was not clearly separated from but progressively merged with the overlying neocortex. Direct sequencing of the 7 coding exons and intron/exon boundaries of the doublecortin (DCX or XLIS) gene did not reveal the presence of any mutation or polymorphism. Patients 6 to 9 were tentatively diagnosed as affected by FCD because increased cortical thickness and blurring of the grey matter/white matter interface were evident at least in some magnetic resonance images (Fig. 1C) . Based on magnetic resonance imaging and electroclinical data, corticectomies were performed, extending to the underlying heterotopia in patients 1 to 5, and surgical specimens were made available for both morphologic and molecular analysis. (C1YC6) Anatomic features of architectural focal cortical dysplasia. The supragranular layers were normal, but layers V and VI were not distinguishable (C1YC2); the midcortical parvalbumin-immunoreactive neuropil was normally distributed (C4) and the apical dendrites of supragranular pyramidal neurons were regularly oriented (C5). However, moderate reactive gliosis (C3) and excessive numbers of white matter neurons (C6) were present. Scale bars = (A1YA2, B1YB2, C1) 400 Km; (C2, C4) 200 Km; (A3YA5, B3, B4, C3, C5, C6) 50 Km.
In the 3 patients affected by focal cryptogenic epilepsy (aged 11, 16, and 24 years), the duration of epilepsy ranged from 8 to 11 years and seizure frequency from 8 to 90. These patients were compared with the patients with MCD of comparable age affected by FCD, PNH, and SBH. The last 2 patients (aged 36 and 41 years) were affected by noninvasive brain tumors not associated with epilepsy. They were compared with the patients with PNH of comparable age.
Morphologic Characterization
In the patients with PNH (patients 1Y4), the neocortical cytoarchitecture was normal (Fig. 1A1) , but many heterotopic neurons were evident in the underlying white matter (Fig. 2) . The heterotopic nodules (Fig. 1A2) were composed by irregularly distributed pyramidal neurons with randomly oriented apical and basal dendrites and smaller cell bodies less intensely MAP2-or SMI311-immunoreactive than the pyramidal neurons in the overlying neocortex (Fig. 1A3) . Areas of reduced cell density were evident within the nodules (29) and elongated, SMI311-immunoreactive, bipolar neurons were present at the nodules_ borders (Fig. 1A5) . No dysplastic neurons were present. The intensity of parvalbumin staining within the nodules was not different from that of the overlying neocortex. Numerous parvalbumin-positive fibers surrounded the nodules without however contacting the heterotopic neurons within the white matter (not shown).
The occipitotemporal cortex of patient 5 was characterized by normal cortical features in layers I to IV (Fig. 1B1) . However, the distinction between layers V and VI was lost, a modest gliosis was present in the infragranular layers, and the grey matter/white matter junction was characterized by an excessive number of heterotopic neurons that progressively merged with the underlying heterotopia (Figs. 1B1, B2, 2A) . The cell density of the subcortical heterotopic band was clearly less than that observed in the cortex (Fig. 1B3Y4 ). Neurons were mainly pyramidal, intensely SMI311-immunoreactive, and frequently characterized by branched apical dendrites or inverted polarity (Fig. 1B4) . No layering was evident, although pyramidal neurons were mostly perpendicularly oriented. The GABAergic innervation of the heterotopic pyramidal neurons, as revealed by parvalbumin staining, was comparable to that of the overlying neocortex. GFAP staining was moderate, mainly along blood vessel perpendicularly crossing the heterotopia (not shown).
In all patients with FCD (patients 6Y9), the supragranular layers were normal (Fig. 1C1) , but the junction between layers V and VI was not recognizable (Fig. 1C2) , and moderate gliosis was present in the infragranular layers (Fig. 1C3) . In addition, many bipolar or pyramidal heterotopic neurons were present in the white matter underlying layer VI (Figs. 1C6, 2D) . The neuronal density within the white matter was greater than that observed in cryptogenic epileptic and nonepileptic controls, a feature common to all MCD cases considered (Fig. 2) . Malformed or giant pyramidal neurons or dysplastic ballooned cells were not detected. Therefore, all cortical specimens were classified as affected by architectural dysplasia (10), thus confirming the data provided by magnetic resonance imaging.
In the cortical samples from the remaining 3 epileptic (patients 10Y12) and nonepileptic patients (patients 13 and 14) , the morphologic analysis revealed preserved cortical layering, regularly oriented pyramidal neurons, normal distribution of parvalbumin immunostaining, no reactive gliosis, and moderate numbers of neurons in the underlying white matter (Fig. 2E) . Therefore, for the absence of any morphologic abnormalities, these specimens were used in immunocytochemistry, immunofluorescence, and Western blot experiments as controls and compared with those obtained from patients with MCD of comparable age.
NMDA Receptor Expression
The composition of NMDA receptors as well as the expression level of associated proteins (12) such as >CaMKII and MAGUK family members (PSD95, SAP 97) was investigated in all cases. In all patients with PNH, immunoreactivity for NR1 and, more clearly, NR2B subunits was reduced in the heterotopic nodules in comparison to the adjacent cortical areas of the same patients and the neocortices of nonepileptic controls (Fig. 3AYF) . Confocal immunofluorescence experiments further demonstrated that the NR2B signal was markedly reduced in the dendrites of neurons within the heterotopic nodules compared with pyramidal FIGURE 2. Heterotopic neurons in the white matter of patients with subcortical band heterotopia (A), periventricular nodular heterotopia (PNH) (B, C), focal cortical dysplasia (FCD) (D), and cryptogenic epilepsy (E). NeuN immunoreactivity. Note the huge number of heterotopic neurons at the grey/ white matter junction in the patient with band heterotopia (A), and the greater density of white matter neurons near the nodules (B) than underlying the neocortex (C) in the patients with PNH. The comparison between the white matter of corresponding frontal regions clearly shows that the number of heterotopic neurons is considerably higher in patients with FCD (D) than that in cryptogenic epilepsy (E). Scale bars = 100 Km.
neurons of overlying cortical areas (Fig. 3G) . Western blot analysis confirmed and extended the immunocytochemical data. Not only the NR1 and NR2B signals were reduced in the heterotopic nodules in comparison to the cortices overlying the PNH and with those obtained from controls of comparable ages, but this reduction was also associated with an even more dramatic decrease of NR2A expression levels (Fig. 3H) . The NR1/NR2A/NR2B reduction was consistently observed in all patients with PNH, in both the homogenate and postsynaptic TIF fractions, and it was statistically significant for both NR2A and NR2B in comparison to the overlying cortical areas (Fig. 3H) . In addition, the NMDA downregulation was further underscored by the statistically significant reduction of the NR1 subunit in postsynaptic membranes of heterotopic nodules compared with the overlying neocortex. Decreased NMDA expression levels were also associated in the total homogenate with concomitant reduced levels of several key components of the glutamatergic synapse (20) such as GluR1, p286/activated >CaMKII, SAP97, and PSD-95 (Fig. 3H) . In the TIF fraction, however, in contrast to what observed for NR2A and NR2B, these reductions were modest and did not reach the level of significance (p 9 0.05 for GluR1, SAP97, and PSD-95, Het versus Ctr). The total >CaMKII signal was by contrast unmodified in all cases, and it was used as loading control for the protein content of the considered fractions (Fig. 3H) (25Y27) . Similar results were also present in the other patient affected by cerebral heterotopia (i.e. patient 5). The immunocytochemistry analysis of NR2B subunit expression in the subcortical band heterotopia, overlying neocortex, and the neocortex from an age-matched (24 years) control patient revealed a gradient of staining in the pyramidal neurons, more intense in the cryptogenic cortex (Fig. 4A) , reduced in the cortex overlying the heterotopia (Fig. 4B) , and very low in the subcortical heterotopic band (Fig. 4C) . Confocal immunofluorescence confirmed the reduced NR2B signal in the dendrites of heterotopic pyramidal neurons within the white matter (compare Fig. 4D with E) . Western blot experiments revealed that NR2A, NR2B and, more modestly, NR1 protein levels were reduced in homogenate and TIF purified from the subcortical heterotopic band when compared with the overlying cortex and with the control cortical sample (Fig. 4F) . Conversely, all other elements of the glutamatergic postsynaptic compartment were mostly unmodified, thus suggesting a specific modification of NR2A and NR2B regulatory subunits of the NMDA receptor in the heterotopic band of this patient.
Finally, we compared the cortical specimens of the 4 patients affected by architectural FCD with the cortical samples from 2 control patients with cryptogenic epilepsy of comparable age. In contrast to nodular and band heterotopia, immunocytochemistry revealed more intense NR1 and particularly NR2B staining in pyramidal neurons of all 4 FCD specimens (Fig. 5AYF) . Cortical pyramidal neurons were more intensely immunoreactive throughout all cortical layers in the soma as well as the basal and apical dendrites. Confocal immunofluorescence confirmed the increased NR2B signal in coarse granules within the cytoplasm of cell bodies and apical dendrites (Fig. 5GYI) . A similar pattern of protein expression was also detected by Western blot analysis, which demonstrated a clearcut increase of the NR2B protein levels in the 4 patients with FCD in comparison to the 2 control patients (Fig. 5J) . The NR2B increase was more evident in the homogenate than in the postsynaptic TIF fraction, but it was statistically significant for both considered protein fractions (Fig. 5J, right) . Other consistent modifications were not found, even if some alterations (i.e. increased NR2A or GluR1) were detected in a single patient but not confirmed in the others. Overall, the increased expression of NR2B represents the major modification in patients with FCD.
Double-Labeling Confocal Immunofluorescence
The cortical samples from patients with MCD, particularly those affected by FCD, were characterized by a variable degree of gliosis. Therefore, to verify whether the observed modifications in the NR2B expression levels could be at least in part the result of the possible contribution of astrocytic NMDA receptors, we performed double-labeling confocal immunofluorescence experiments with anti-NR2B and anti-GFAP antibodies. As clearly shown in Figure 6 , in the cortical areas of patients with MCD, reactive astrocytes were intensely GFAP labeled but did not reveal NR2B staining, which was restricted to neuronal cell bodies and dendrites (Fig. 6A, B) . (J) Western blot analysis of NR2B, NR2A, NR1, GluR1, SAP97, PSD-95, p286-active, and total >CaMKII performed in the homogenate (left) and in TIF (right) purified from the cortex of the 4 patients with FCD (Dys) and from the cortex of 2 controls with focal cryptogenic epilepsy of comparable age (Ctr). Note that NR2B expression levels are increased in all patients with FCD, whereas NR2A (patient 8, aged 7 years) or GluR1 (patient 7, aged 10 years) expression levels are increased in some but not all patients. The histogram (lower right) quantifies the expression levels of NR1, NR2A, and NR2B subunits in FCD versus control patients. Data are indicated as mean percentages T standard deviation of controls. Statistical analysis reveals that NR2B was significantly increased in dysplastic versus control cortical areas. **, p G 0.01 in the homogenate; *, p G 0.05 in postsynaptic membranes. Scale bars = (AYC) 20 Km; (DYF) 50 Km; 20 Km in inserts; (GYI) 20 Km.
DISCUSSION
In the present study, we have investigated the expression level and subunit composition of the NMDA receptor in a series of patients affected by drug-resistant focal epilepsy and cerebral malformations. By means of a combined morphologic and molecular approach, we have shown that the levels of specific NMDA receptor subunits are altered in all patients with MCD. In addition, we have demonstrated that in the 5 patients with heterotopia, i.e. with cerebral malformations resulting from altered neuronal migration (1), the expression of NMDA receptor subunits, particularly NR2A and NR2B, was significantly downregulated, whereas in the 4 patients with FCD, i.e. with cerebral malformations resulting from altered cortical organization (1), there was a selective and significant increase in the expression levels of the NR2B subunit.
Before discussing our data, some methodological considerations regarding the choice of appropriate controls should be put forward. Ideally, the best control for an epileptic patient with a brain dysgenesis in a given brain area should be the corresponding brain region from a nonepileptic control of the same age. Our nonepileptic control samples have been obtained from surgically resected, normal cortical areas adjacent to noninvasive brain tumors from patients much older than the majority of our patients with MCD/epilepsy, particularly if affected by FCD. Because the expression levels of NMDA receptor subunits are precisely developmentally regulated (30) , the choice of controls of comparable age is a key factor in our study. Therefore, we have used agematched cryptogenic epilepsy patients as controls for the young patients affected by FCD, BH, and PNH, and the older nonepileptic patients as controls for the age-matched patients with PNH (36 and 41 years and 29 and 42 years, respectively). In addition, regional variations in NMDA expression levels between different cortical areas could also have influenced the results of our analysis (31) . However, because we found very similar results in both PNH and FCD cases, although derived from different lobes, it is unlikely that a localization-related effect may have altered the biologic significance of our data.
Different studies have already addressed the expression of NMDA receptor subunits in epileptic patients affected by focal cortical dysplasia (16, 18, 19, 32Y34) . Direct comparison between the present data and the existing literature needs to be done cautiously, because different technical approaches have been used, different control tissues have been used, and patients with FCD with different severity of cytoarchitectural abnormalities have been considered. Notwithstanding these limitations, with the exception of a single report (34) , all studies were consistent in demonstrating the upregulation of the NR2B expression level in patients with FCD. The group from the Cleveland Clinic Foundation reported excess NMDA NR2A/B receptors (16) , increased coexpression of NR2A/B and NR1 subunit proteins (32) , and increased NR2B/PSD-95 coassembly (33) in dysplastic neurons of human epileptic cortex, suggesting that excess NR2B receptor subunits were likely anchored to the postsynaptic membrane. The same group also reported that epileptiform activities in the dysplastic cortex were blocked by the NR2B-specific NMDA receptor inhibitor ifenprodil, thus suggesting that increased NR2B expression contributed to epileptogenesis in patients with FCD (19) . Another group analyzed single cell mRNA from cortical samples resected for epilepsy surgery, demonstrating increased NR2B mRNA and decreased NR2A and GABA receptor mRNA in dysplastic neurons compared with heterotopic or control pyramidal neurons (18) . Our data confirm these reports and also demonstrate that the NR2B upregulation is a specific feature of the epileptic neurons of patients with architectural FCD, because increased NR2B levels are not present in epileptic but nondysplastic patients of the same age. The downregulation of NR2A mRNA (18) and the upregulation of PSD-95 expression levels (33) in the dysplastic cortex, not confirmed by the present study, may be the result of the different methodologies or subcellular fractionation procedures used in our article and the presence of misshapen and giant cortical pyramidal neurons (i.e. to the more severe cytoarchitectural abnormalities) not observed in our patients with FCD.
The specific reason why increased NR2B expression level may lead to the development of hyperexcitability and the genesis of epileptic discharges in FCD yet remains to be established. To obtain a more clear and comprehensive scenario of the proteins composing the postsynaptic compartment, we also analyzed the GluR1 subunit of AMPA receptor, p286-active >CaMKII, and members of the MAGUK protein family. No selective or relevant differences in the expression levels of these proteins have been detected, thus suggesting that NR2B increase is the major modification in FCD areas. NMDA receptors composed by coassembled NR1 and NR2B subunits are mainly expressed during neuronal ontogenesis. They are functionally characterized by higher peak ionic currents and slower inactivation time, therefore resulting in greater Ca 2+ and Na + influx (30, 35) . For these features, it has been hypothesized that enhanced coexpression of NR1/ NR2B subunits may reflect the altered maturation of FCD FIGURE 6. NR2B and GFAP double-labeling confocal immunofluorescence in the neocortex of periventricular nodular heterotopia (PNH) (patient 3) and focal cortical dysplasia (FCD) (patient 7) cases. Note that in both PNH (A) and FCD (B) cortical samples, the GFAP immunolabeling (red) is almost completely segregated from that of NR2B staining (green). Scale bars = 20 Km.
neurons and that the NMDA-mediated increased ionic influx may contribute to epileptiform activities of this brain malformation. However, our Western blot analysis, showing increased NR2B levels greater in the total protein homogenate than in postsynaptic fraction, indicates that relevant modifications of NR2B levels are also present in cell compartments other than synaptic membranes. This finding can be explained either by a defect in the trafficking process of NR2B or by an extrasynaptic localization of this receptor subunit, which has been reported to be related to signaling pathways of cell death (36, 37) . Consistent with this result, our morphologic data did not demonstrate selective enhancement of NR2B staining of the postsynaptic membrane. It seems, therefore, that the mechanisms underlying hyperexcitability in FCD neurons are more complex than the mere increased ionic influx through the postsynaptic membrane.
If compared with focal cryptogenic epilepsy, patients with FCD are characterized by earlier epilepsy onset, higher seizure frequency, and recurrent episodes of epileptic status (38) . Therefore, the possibility that the NR2B increase observed in FCD samples may be in part a secondary phenomenon (induced by recurrent epileptic activity) should also be considered. Supporting this hypothesis, previous data have indicated that in the rat hippocampus, NR2B can be upregulated in an activity-dependent manner (39) and NMDAdependent glutamatergic transmission enhanced by epileptiform activity (40) . In addition, NR2B is upregulated in Rasmussen encephalitis (15) , an invariably progressive acquired condition characterized by malignant, high-frequency focal seizures (41) .
At variance with the results obtained in FCD cases, our data clearly demonstrate a reduction of NMDA receptor expression, more pronounced for NR2A and NR2B regulatory subunits, in both the homogenate and postsynaptic membrane fractions of neurons within nodular and band heterotopia. Both periventricular nodular and subcortical band heterotopia are the result of early impairment of the proper migration of a population of neurons. In both types of heterotopia, some morphologic features of heterotopic neurons such as the reduced cell size and the presence of branched or randomly oriented dendrites are possible signs of altered neuronal maturation. In contrast to what observed in FCD, however, the altered maturation in PNH was consistently associated with reduced rather than increased NR2A and NR2B subunit expression in all considered cases. This finding is likely unrelated to age, because it was observed in patients of considerably different ages (from 13Y42 years). The longer duration of epilepsy in patients with heterotopia compared with FCD cases may be an important factor in determining the molecular structure of postsynaptic NMDA receptors. However, it should be stressed that in patients with heterotopia, the long duration of epilepsy was not necessarily associated with high seizure frequency (Table) , and we observed very similar findings in patients with epileptic histories of considerably different length (from 12Y28 years).
We have previously demonstrated in a rat model of cerebral heterotopia (i.e. rats prenatally treated with methylazoxymethanol-acetate [MAM]) (42), a selective reduction of NR2A/B targeting to the postsynaptic membrane associated with an impairment of the CaMKII-dependent NR2A/B phosphorylation in the heterotopic cortical areas (23) . Those data led us to hypothesize that the observed alteration of the NMDA/>CamKII complex may contribute to the hyperexcitability of cerebral heterotopia in MAM rats (23) . The present data, obtained from epileptogenic human heterotopia, confirm and extend those findings, suggesting that the alteration of the glutamatergic NMDA synapse plays a role also in the hyperexcitability of heterotopic neurons in human patients. Even if other key components of the glutamatergic synapse such as GluR1, SAP97, and PSD-95 proteins are reduced in the heterotopic nodules, the NR2A and NR2B reduction is the only significant abnormality observed in postsynaptic membranes. This selective impairment of the regulatory subunits of the NMDA receptor complex may alter the fine-tuning of the excitability of the heterotopic neuron and contribute to its hyperexcitability through molecular mechanisms yet to be clarified. It should be also considered an alternative hypothesis, that is, that the observed NMDA abnormalities may reflect the altered maturation of the heterotopic neurons rather than being related to epileptogenesis. Even if a direct link between NMDA/>CamKII complex impairment and neuronal hyperexcitability is suggested by a number of reports (reviewed in [23] ), the studies on human subjects, for their observational nature, are not the best option to demonstrate the cellular and molecular mechanisms leading to epileptogenesis in cerebral malformations. However, this report clearly underscores the relevance of NMDA receptor abnormalities in different types of human MCDs.
